Malignant lymphoma presenting as fulminant hepatic failure

ELIZABETH NIZALIK, MD, EKREM ZAYED, MD, FRCPC, ANNETTE FOYLE, MD, CM, FRCPC, FCAP

ABSTRACT: A patient with fulminant hepatic failure who had a T8 malignant lymphoma is described. A review of the literature yields 11 other cases with hematologic malignancies with similar presentation. To the authors’ knowledge this is the first case in which cell marker analysis was performed. Pitfalls in morphologic diagnosis are discussed. Can J Gastroenterol 1989;3(3):111-114

Key Words: Fulminant hepatic failure, Immunoblastic, T8 lymphoma, Malignant lymphoma, Polymorphous

Le lymphome malin et l’insuffisance hépatique fulminante

RESUME: Le cas d’un patient atteint d’insuffisance hépatique fulminante et ayant un lymphome malin T8 est décrit. Une étude des publications portant sur le sujet révèle 11 autres cas de tumeurs malignes hématologiques se présentant de la même manière. D’après l’auteur, il s’agit du premier cas pour lequel une analyse utilisant les marqueurs cellulaires a été effectuée. Les pièges du diagnostic morphologique sont examinés.

LIVER INVOLVEMENT DURING THE course of both Hodgkin’s and non-Hodgkin’s lymphoma is not unusual (1) and jaundice may develop (2,3). However, fulminant hepatic failure is rarely a presenting feature of malignant lymphomas and, when it occurs, the clinical picture may strongly suggest virus, alcohol or drug induced hepatitis (4). A case whose presentation with malignant lymphoma was dominated by fulminant and fatal hepatic failure is described. A review of the literature yields 11 other cases with a similar presentation (6-11).

CASE PRESENTATION

A 66-year-old caucasian woman was hospitalized having presented with lethargy, anorexia and vomiting of several days duration. The patient also noted decreasing energy and a 2.5 kg weight loss over a period of one year since having a tooth abscess complicated by sep-
ticemia. There were no other symptoms. The patient did not consume alcohol and there was no history of blood transfusions; hypertension was treated with a diuretic. Physical examination revealed fever (38.3°C) and an erythematous pharynx with no exudate. The remainder of the examination was normal, including the abdominal examination.

Investigations revealed hemoglobin 1145 g/L, white blood cell count 6600/mm³ and hyponatremia (sodium 127 mEq/L). Despite supportive, steroid and ampicillin treatment, on day 6 the patient’s abdomen became distended and tender with right upper quadrant pain and peripheral edema. This was accompanied by hyperbilirubinemia, hypoproteinemia and thrombocytopenia. On transfer to the authors’ hospital on the next day, blood pressure was 110/80 mmHg, respiratory rate 24/min, pulse 100 beats/min and temperature 38.7°C. The patient was lethargic and oriented to person only. There was dehydration, jaundice, anasarca, palmar erythema, asterixis and oral petechiae. The abdomen was obese but also distended and soft, and there was shifting dullness.

On day 7 of the illness (transfer day) the laboratory investigations were as follows: hemoglobin 107 g/L; platelets 1600/mm³; white blood cell count 6500/mm³; neutrophils 4000/mm³; lymphocytes 2000/mm³; aspartate aminotransferase 195 (normal 8 to 29 iu/L); alanine aminotransferase 132 (normal 1 to 41 iu/L); lactate dehydrogenase 2405 (normal 117 to 259 iu/L); and alkaline phosphatase 402 (normal 30 to 104 iu/L). Total bilirubin was 95 (normal 0 to 16 µM/L); albumin 23 (normal 38 to 50 g/L); ammonia 76 (normal 5 to 35 µM/L); partial thromboplastin time 33.5 (normal 25 to 35 s); and prothrombin time 13.5 (normal 10.5 to 12.5 s).

The steroids were continued and the antibiotic was changed to ticarcillin and tobramycin. Platelet transfusions were given. The patient developed bilateral pleural effusions, metabolic acidosis and encephalopathy. Lactulose was started. Bone marrow aspirates were done on the eighth and ninth days of illness. On the 10th day, the hemoglobin fell from 82 to 51 g/L and blood transfusions were given. The patient suffered cardiac arrest later that day and died. The clinical differential was viral hepatitis or a lymphoproliferative disorder. Serum was negative for hepatitis B surface antigen (HBsAg) and antibody to HBsAg. Serology for hepatitis A was not performed.

**BONE MARROW**

The first bone marrow aspirate showed some atypical lymphoid cells but this was not diagnostic and a second specimen was requested. The second bone marrow aspirate showed replacement of normal marrow with lymphoid cells with nuclei of varying size and shape with nucleoli and mitoses. Some similar small abnormal lymphoid cells were present in the peripheral blood and these increased in number terminally. Erythroagocytosis was seen in benign histiocytes.

Cell surface marker analysis was performed on cells obtained from the second bone marrow aspirate, using a method from Ortho Diagnostic Systems Inc (Raritan, New Jersey). Mouse monoclonal antibodies OKT3, OKT4, OKT8 and OK111 from Ortho Diagnostic Systems, and NKH1 from Coulter and B from Meloy were used.

The bone marrow was collected in heparin, centrifuged and the plasma was discarded. The cells were resuspended in phosphate buffered saline. Mononuclear cells were separated by Ficoll-Paque density solution and washed twice in phosphate buffered saline with 2% serum. The cells were resuspended in 1.0 mL phosphate buffered saline with 2% serum and the cell count was adjusted to 1 x 10⁷ cells/mL. The cells were incubated with the mouse monoclonal antibodies and Ortho FITC-conjugated goat antimouse IgG was added. The cells were counted with the fluorescent microscope. Terminal deoxynucleotidyl transferase was done by an immunoperoxidase technique from Supertechs Inc (Bethesda, Maryland). The following results were obtained: 82% of the bone marrow lymphoid cells were mature T lymphocytes expressing the T3 antigen; 76% were T8 cells; 5% were T4 cells; and terminal deoxynucleotidyl transferase was negative.

**AUTOPSY RESULTS**

The liver was cholestatic and weighed 1700 g. There was no biliary obstruction and there was mild splenomegaly (250 g). The cystic duct, pancreatic and one para-aortic lymph nodes were enlarged (2.5 cm each).

Histology showed diffuse non-Hodgkin's lymphoma involving thoracic and abdominal lymph nodes, spleen and bone marrow; liver, myocardium, lungs, kidney and cervix. The infiltrate was pleomorphic, consisting of bizarre atypical lymphocytes. The nucleus varied in
size and shape. Some nuclei were hyperchromatic and hyperlobated, while others were vesicular with prominent nucleoli. Some cells resembled Reed-Sternberg cells (Figure 1). There were widespread infiltrates in portal tracts and adjacent sinusoids with cholestasis (Figure 2). The remaining hepatocytes appeared normal. Candida albicans epiglottitis and esophagitis were also noted.

DISCUSSION

Fulminant hepatic failure is defined as a clinical syndrome of sudden onset resulting from severe impairment of liver function (5). There should be no pre-existing liver disease. The most common cause is massive hepatic necrosis due to acute viral hepatitis A, hepatitis B or non-A, non-B hepatitis. In this case, the syndrome should occur within eight weeks of onset of symptoms. Alcohol and drugs such as halothane, monoamine oxidase inhibitors, isoniazid and acetaminophen have also been reported to give rise to fulminant hepatic failure. Less commonly, fatty liver of pregnancy and surgical shock are responsible. Lymphoma is distinctly an uncommon cause.

A review of the literature yielded 11 other patients with lymphoproliferative and malignant histiocytic disorders who presented in a similar fashion with fulminant hepatic failure (6-11) (Table 1). The patients, seven males and four females, ranged in age from 24 to 79 years. Death occurred within 48 h to three months. In nine cases the liver failure was clinically attributed to acute infectious or drug induced hepatitis; only two cases were attributed to neoplastic disease. The diseases were Hodgkin’s disease (five cases), non-Hodgkin’s lymphoma (two cases) and malignant histiocytosis (three cases). One was designated only as primitive lymphoreticular malignancy but was suspected to be malignant histiocytosis. At autopsy, all except one patient showed tumour involvement of the liver. In most cases, involvement of the spleen and lymph node was noted. In the exception, the bile duct was obstructed by involved porta hepatic nodes.

The present case resembled some of the above cases morphologically. It is interesting to note that Colby and Labrecque (6) describe a polymorphous infiltrate with bizarre hyperlobated nuclei and some erythrophagocytosis, particularly in view of the erythrophagocytosis the authors observed in benign histiocytes. To the authors’ knowledge, the present case is the first such case in which the cell surface markers were considered.

### TABLE 1

Other cases of malignant lymphoma presenting as fulminant hepatic failure

<table>
<thead>
<tr>
<th>Reference</th>
<th>Age (sex)</th>
<th>Autopsy diagnosis</th>
<th>Premortem Biopsy</th>
<th>HAV-IgM</th>
<th>HBsAg</th>
<th>HBsAb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Braude et al (7)</td>
<td>24 M</td>
<td>Non-Hodgkin’s lymphoma</td>
<td>Bone marrow</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Zafarani et al (11)</td>
<td>66 F</td>
<td>Burkitt’s lymphoma</td>
<td>Bone marrow</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Colby and Labrecque (6)</td>
<td>30 F</td>
<td>Malignant histiocytosis</td>
<td>Bone marrow</td>
<td>na</td>
<td>Negative</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td>30 M</td>
<td>Malignant histiocytosis</td>
<td>Bone marrow</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td>60 M</td>
<td>Malignant histiocytosis</td>
<td>Bone marrow</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td>65 M</td>
<td>Primitive lymphoreticular malignancy? Malignant histiocytosis</td>
<td>Bone marrow</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Leifowitch et al (10)</td>
<td>79 F</td>
<td>Hodgkin’s lymphoma mixed cellularity</td>
<td>Bone marrow</td>
<td>na</td>
<td>na</td>
<td>Positive</td>
</tr>
<tr>
<td>Trewby et al (8)</td>
<td>49 M</td>
<td>Hodgkin’s lymphoma</td>
<td>Bone marrow</td>
<td>na</td>
<td>Negative</td>
<td>na</td>
</tr>
<tr>
<td>Fairbank (9)</td>
<td>33 F</td>
<td>Hodgkin’s sarcoma</td>
<td>Bone marrow</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td>77 M</td>
<td>Hodgkin’s sarcoma</td>
<td>Bone marrow</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td>52 M</td>
<td>Hodgkin’s granuloma</td>
<td>Bone marrow</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
</tbody>
</table>

M Male; F Female; na Not available
The cells were mature T lymphocytes which expressed the T3 antigen and were of the T8 cytotoxic-suppressor subset.

Histologically, the authors designated this as malignant lymphoma, large cell immunoblastic and polymorphous in the working formulation (12). This subtype of high grade immunoblastic lymphoma was included in the formulation to encompass the wide spectrum of T cell lymphoma reported in Japan and referred to as adult T cell lymphoma-leukemia (13). These neoplasms are endemic in southwestern Japan and are associated with a type C retrovirus, HTLV-1. The patients have lymphadenopathy with no mediastinal mass. They may have hepatosplenomegaly, skin involvement and osteolytic bone lesions with hypercalcemia. The median survival is less than one year. Histologically, the large majority of cases (80%) are of medium sized cell type and pleomorphic type. In the latter, there are prominent giant cells, sometimes resembling Reed-Sternberg cells. Nuclear polymorphism is a striking feature of all subtypes. All Japanese cases are of the T4 helper-inducer subset. However, adult T cell lymphoma-leukemia has been described in other racial groups (14,15) and in nonendemic areas; some T8 phenotypes have been reported (15).

ACKNOWLEDGEMENTS: The authors thank Dr Bruce Burns of the Ottawa Civic Hospital and Dr M. O'Shaughnessy of the Viral Surveillance Section at the Laboratory Centre for Disease Control, Ottawa, Ontario for their assistance with the antibody testing.

REFERENCES
